These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intracerebroventricular passive immunization. I. The effect of intracerebroventricular administration of an antiserum to tumor necrosis factor-alpha on the plasma adrenocorticotropin response to lipopolysaccharide in rats.
    Author: Turnbull AV, Rivier CL.
    Journal: Endocrinology; 1998 Jan; 139(1):119-27. PubMed ID: 9421406.
    Abstract:
    The present study tested the hypothesis that the cytokine tumor necrosis factor-alpha (TNF-alpha) is an important central nervous system mediator of the rat hypothalamo-pituitary-adrenal (HPA) axis response to the i.v. administration of lipopolysaccharide (LPS; 5 microg/kg). LPS produced a rapid (within 30 min) rise in plasma TNF-alpha levels, which preceded elevations in plasma ACTH (commencing at 45 min). Despite a lack of detectable TNF-alpha biological activity in the brain 30 min to 2 h after LPS administration, intracerebroventricular (i.c.v.) pretreatment (-20 h) with 5 microl anti-TNF-alpha antiserum significantly delayed the onset of the plasma ACTH response to LPS, suggesting that TNF-alpha acts within the brain. However, we also noted that the i.c.v. infusion of anti-TNF-alpha 20 h earlier produced experimentally significant concentrations of the same anti-TNF-alpha antibodies in systemic blood. This suggested the possibility that the effect of this antiserum was due to its leakage to the periphery. Indeed, 5 microl anti-TNF-alpha administered i.v. at -20 h produced an inhibition of the ACTH response to LPS that was temporally and quantitatively similar to that produced by i.c.v. anti-TNF-alpha. Intracerebroventricular administration of anti-TNF-alpha immediately before LPS produced only low systemic blood levels of corresponding anti-TNF-alpha antibodies and did not significantly alter the plasma ACTH response, whereas i.v. administration of anti-TNF-alpha immediately before LPS was clearly effective. Collectively, these results show that 1) biologically active levels of TNF-alpha in systemic plasma and the ensuing ACTH responses to LPS were always temporally and qualitatively related; and 2) even though i.c.v. administration of anti-TNF-alpha could inhibit the HPA axis response to LPS, this was apparent only when substantial amounts of anti-TNF-alpha antibodies had reached systemic blood. We, therefore, conclude that at the dose of LPS used in this study (5 microg/kg), TNF-alpha is an important mediator of the HPA axis response to LPS by an action within the periphery, but probably not within the brain.
    [Abstract] [Full Text] [Related] [New Search]